+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Kidney Disease Medication Market - Global Forecast 2026-2032- Product Image
Chronic Kidney Disease Medication Market - Global Forecast 2026-2032- Product Image
Sale

Chronic Kidney Disease Medication Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6128909
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Kidney Disease Medication Market is projected to reach USD 16.25 Billion in 2026. It is expected to continue growing at a CAGR of 4.85%, reaching USD 21.65 Billion by 2032.

Chronic Kidney Disease Medication: Executive Summary

Chronic kidney disease medication encompasses therapies used to slow disease progression, manage complications, and address associated conditions such as hypertension, diabetes, anemia, mineral and bone disorders, and cardiovascular risk. Treatment decisions depend on kidney function, albuminuria, comorbidities, safety considerations, access, and stage-specific clinical guidance. The field is shifting toward earlier detection and integrated risk management rather than relying solely on late-stage renal replacement planning.

Care Is Shifting Toward Earlier, Integrated Disease Management

Clinical practice is increasingly emphasizing risk stratification, routine assessment of estimated glomerular filtration rate and albuminuria, and coordinated management of diabetes, blood pressure, cardiovascular risk, and medication safety. Therapeutic selection is also becoming more individualized as clinicians balance renal protection, adverse-event risk, adherence, drug interactions, and changing kidney function. Persistent challenges include delayed diagnosis, fragmented care, uneven screening, treatment affordability, and limited specialist capacity, particularly in settings with constrained health-system resources.

Artificial Intelligence Supports Detection, Stratification, and Medication Stewardship

Artificial intelligence can strengthen chronic kidney disease care by identifying patients at elevated risk from electronic health records, laboratory trends, imaging, and clinical documentation. Potential applications include earlier case finding, progression-risk stratification, treatment-response monitoring, adverse-event surveillance, and decision support for dose adjustment. Real-world value depends on representative training data, external validation, explainability, privacy safeguards, interoperability, and clinician oversight. AI should augment-not replace-clinical judgment, especially where comorbidities and incomplete data complicate treatment decisions.

Regional Differences Reflect Screening, Access, and Health-System Capacity

North America generally combines broad access to diagnostics and specialty care with persistent affordability, adherence, and inequity concerns. Europe benefits from established clinical guidelines and coordinated health systems, although reimbursement and implementation differ across countries. Asia-Pacific spans highly advanced systems and areas with limited screening, creating substantial variation in diagnosis and treatment continuity. Latin America faces uneven access, out-of-pocket pressure, and infrastructure gaps, while the Middle East is shaped by diabetes prevalence, specialized-care concentration, and differing national coverage models. Africa continues to confront late presentation, limited laboratory and nephrology capacity, supply constraints, and the need for scalable primary-care approaches.

Economic and Alliance Groups Reveal Uneven Policy and Access Priorities

ASEAN markets require approaches that accommodate substantial differences in financing, urbanization, workforce capacity, and medicine availability. BRICS members combine significant clinical and manufacturing capabilities with varied insurance structures and regional disparities. The European Union benefits from shared regulatory and guideline frameworks but retains national differences in reimbursement and service delivery. G7 systems typically have stronger research and diagnostic infrastructure, yet aging populations and healthcare-cost pressures remain important concerns. GCC countries often possess substantial healthcare investment and specialized facilities, while workforce reliance and population heterogeneity influence care models. NATO members span diverse health systems, making common priorities in preparedness, data exchange, and continuity of essential treatment particularly relevant.

Country Contexts Shape Diagnosis, Reimbursement, and Treatment Continuity

Australia combines universal coverage with geographic access challenges, especially for remote communities. Brazil faces regional inequality and the need to strengthen early detection within public care. Canada must address rural and Indigenous access alongside provincial variation. China is expanding chronic-disease management while managing urban-rural differences and a large patient population. France, Germany, Italy, and Spain operate within mature European systems but differ in reimbursement pathways, primary-care coordination, and regional implementation. India confronts affordability, late diagnosis, and uneven specialist access, while Japan and South Korea combine advanced clinical capacity with aging-related demand and pressure for efficient long-term management. Mexico continues to face diabetes-related kidney risk and uneven access. Russia’s care environment is influenced by geographic scale and variable availability. The United Kingdom emphasizes guideline-led, publicly funded care but must manage capacity, regional variation, and inequalities. The United States offers extensive therapeutic and diagnostic capability while facing high costs, fragmented delivery, and disparities in access.

Industry Leaders Should Prioritize Evidence, Access, and Responsible Digital Integration

Leaders should align product and service strategies with stage-specific clinical needs, renal and cardiovascular outcomes, and practical medication adherence. Evidence generation should include diverse populations, real-world effectiveness, safety in comorbid patients, and clear monitoring requirements. Access plans should address affordability, distribution reliability, health-literacy barriers, and partnerships with primary-care networks. Digital investments should focus on interoperable data, validated risk tools, transparent AI governance, and workflows that reduce rather than increase clinician burden. Organizations should also prepare for tighter scrutiny of comparative effectiveness, value, environmental considerations, and continuity of supply.

Methodology: Evidence Synthesis Across Clinical, Policy, and Access Dimensions

This executive summary uses a structured qualitative synthesis of established clinical concepts, public-health priorities, health-system characteristics, and technology applications relevant to chronic kidney disease medication. The assessment compares regional, economic-group, and country contexts using factors such as disease-management practice, diagnostic capacity, reimbursement, care delivery, workforce, affordability, and digital readiness. Claims are framed as directional, evidence-grounded observations rather than market estimates. Interpretation should be updated as clinical guidance, regulatory policy, safety evidence, and national treatment pathways evolve.

The Strategic Priority Is Earlier, Equitable, and Data-Informed Kidney Care

Chronic kidney disease medication is moving toward integrated risk reduction, earlier intervention, and more personalized monitoring. Progress will depend not only on therapeutic innovation but also on reliable diagnosis, primary-care integration, affordable access, workforce development, and responsible use of data and AI. Leaders that connect clinical evidence with practical delivery models can help improve treatment continuity and outcomes across highly diverse health systems, while maintaining patient safety and equity as central priorities.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Chronic Kidney Disease Medication Market, by Drug Class
7.1. Introduction
7.2. Renin Angiotensin System Modulators
7.2.1. Angiotensin Converting Enzyme Inhibitors
7.2.2. Angiotensin Receptor Blockers
7.2.3. Direct Renin Inhibitors
7.2.4. Angiotensin Receptor Neprilysin Inhibitors
7.3. Sodium Glucose Cotransporter Inhibitors
7.3.1. SGLT2 Inhibitors
7.3.2. Dual SGLT1 And SGLT2 Inhibitors
7.4. Mineralocorticoid Receptor Antagonists
7.4.1. Steroidal Mineralocorticoid Receptor Antagonists
7.4.2. Nonsteroidal Mineralocorticoid Receptor Antagonists
7.5. Erythropoiesis Stimulating Agents
7.5.1. Short Acting Erythropoiesis Stimulating Agents
7.5.2. Long Acting Erythropoiesis Stimulating Agents
7.5.3. Continuous Erythropoiesis Receptor Activators
7.6. Iron Therapies
7.6.1. Intravenous Iron Therapies
7.6.1.1. Iron Sucrose
7.6.1.2. Ferric Carboxymaltose
7.6.1.3. Ferric Derisomaltose
7.6.2. Oral Iron Therapies
7.6.2.1. Ferrous Salt Preparations
7.6.2.2. Ferric Salt Preparations
7.6.2.3. Polysaccharide Iron Complexes
7.7. Phosphate Binders
7.7.1. Calcium Based Phosphate Binders
7.7.2. Sevelamer Based Phosphate Binders
7.7.3. Lanthanum Based Phosphate Binders
7.7.4. Iron Based Phosphate Binders
7.8. Potassium Binders
7.8.1. Sodium Polystyrene Sulfonate
7.8.2. Patiromer
7.8.3. Sodium Zirconium Cyclosilicate
7.9. Vitamin D And Analogs
7.9.1. Active Vitamin D Analogs
7.9.2. Nutritional Vitamin D Supplements
7.10. Calcimimetics
7.11. Diuretics
7.11.1. Loop Diuretics
7.11.2. Thiazide And Thiazide Like Diuretics
7.11.3. Potassium Sparing Diuretics
7.12. Uric Acid Lowering Agents
7.12.1. Xanthine Oxidase Inhibitors
7.12.2. Uricosuric Agents
7.13. Lipid Lowering Therapies
7.13.1. Statins
7.13.2. Ezetimibe And Related Agents
7.13.3. PCSK9 Inhibitors
7.14. Immunosuppressive Agents
7.14.1. Corticosteroids
7.14.2. Calcineurin Inhibitors
7.14.3. Antiproliferative Agents
7.14.4. Biologic Immunosuppressants
8. Chronic Kidney Disease Medication Market, by Route Of Administration
8.1. Introduction
8.2. Oral Route
8.3. Intravenous Route
8.4. Subcutaneous Route
8.5. Intramuscular Route
9. Chronic Kidney Disease Medication Market, by End User
9.1. Introduction
9.2. Hospitals
9.3. Dialysis Centers
9.4. Nephrology And Specialty Clinics
9.5. Home Care Settings
9.6. Academic And Research Institutions
10. Chronic Kidney Disease Medication Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Dialysis Center Pharmacies
11. Chronic Kidney Disease Medication Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Chronic Kidney Disease Medication Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Chronic Kidney Disease Medication Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Amgen Inc.
15.2. AstraZeneca PLC
15.3. Baxter International Inc.
15.4. Bayer Aktiengesellschaft
15.5. Boehringer Ingelheim International GmbH
15.6. Eli Lilly and Company
15.7. Fresenius Medical Care AG & Co. KGaA
15.8. Otsuka Pharmaceutical Co., Ltd.
15.9. Sanofi S.A.
15.10. Vifor Pharma AG
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Chronic Kidney Disease Medication Market, Years Considered for the Study
FIGURE 2. Global Chronic Kidney Disease Medication Market, Research Design
FIGURE 3. Global Chronic Kidney Disease Medication Market, Research Framework
FIGURE 4. Global Chronic Kidney Disease Medication Market, Data Triangulation
FIGURE 5. Global Chronic Kidney Disease Medication Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Chronic Kidney Disease Medication Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Chronic Kidney Disease Medication Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Chronic Kidney Disease Medication Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Chronic Kidney Disease Medication Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Chronic Kidney Disease Medication Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Chronic Kidney Disease Medication Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Chronic Kidney Disease Medication Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Chronic Kidney Disease Medication Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Chronic Kidney Disease Medication Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Chronic Kidney Disease Medication Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Chronic Kidney Disease Medication Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Chronic Kidney Disease Medication Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Chronic Kidney Disease Medication Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Chronic Kidney Disease Medication Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Chronic Kidney Disease Medication Market Segmentation & Coverage
TABLE 2. Global Chronic Kidney Disease Medication Market Size, 2017-2032 (USD Million)
TABLE 3. Global Chronic Kidney Disease Medication Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Renin Angiotensin System Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Renin Angiotensin System Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Renin Angiotensin System Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Angiotensin Converting Enzyme Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Angiotensin Converting Enzyme Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Angiotensin Converting Enzyme Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Angiotensin Receptor Blockers Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Angiotensin Receptor Blockers Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Angiotensin Receptor Blockers Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Direct Renin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Direct Renin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Direct Renin Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Angiotensin Receptor Neprilysin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Angiotensin Receptor Neprilysin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Angiotensin Receptor Neprilysin Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Sodium Glucose Cotransporter Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Sodium Glucose Cotransporter Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Sodium Glucose Cotransporter Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global SGLT2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global SGLT2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global SGLT2 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Dual SGLT1 And SGLT2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Dual SGLT1 And SGLT2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Dual SGLT1 And SGLT2 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Mineralocorticoid Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Mineralocorticoid Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Mineralocorticoid Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Steroidal Mineralocorticoid Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Steroidal Mineralocorticoid Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Steroidal Mineralocorticoid Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Nonsteroidal Mineralocorticoid Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Nonsteroidal Mineralocorticoid Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Nonsteroidal Mineralocorticoid Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Erythropoiesis Stimulating Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Erythropoiesis Stimulating Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Erythropoiesis Stimulating Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Short Acting Erythropoiesis Stimulating Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Short Acting Erythropoiesis Stimulating Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Short Acting Erythropoiesis Stimulating Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Long Acting Erythropoiesis Stimulating Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Long Acting Erythropoiesis Stimulating Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Long Acting Erythropoiesis Stimulating Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Continuous Erythropoiesis Receptor Activators Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Continuous Erythropoiesis Receptor Activators Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Continuous Erythropoiesis Receptor Activators Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Iron Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Iron Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Iron Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Intravenous Iron Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Intravenous Iron Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Intravenous Iron Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Iron Sucrose Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Iron Sucrose Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Iron Sucrose Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Ferric Carboxymaltose Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Ferric Carboxymaltose Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Ferric Carboxymaltose Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Ferric Derisomaltose Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Ferric Derisomaltose Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Ferric Derisomaltose Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Oral Iron Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Oral Iron Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Oral Iron Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Ferrous Salt Preparations Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Ferrous Salt Preparations Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Ferrous Salt Preparations Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Ferric Salt Preparations Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Ferric Salt Preparations Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Ferric Salt Preparations Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Polysaccharide Iron Complexes Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Polysaccharide Iron Complexes Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Polysaccharide Iron Complexes Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Phosphate Binders Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Phosphate Binders Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Phosphate Binders Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Calcium Based Phosphate Binders Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Calcium Based Phosphate Binders Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Calcium Based Phosphate Binders Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Sevelamer Based Phosphate Binders Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Sevelamer Based Phosphate Binders Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Sevelamer Based Phosphate Binders Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Lanthanum Based Phosphate Binders Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Lanthanum Based Phosphate Binders Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Lanthanum Based Phosphate Binders Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Iron Based Phosphate Binders Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Iron Based Phosphate Binders Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Iron Based Phosphate Binders Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Potassium Binders Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Potassium Binders Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Potassium Binders Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Sodium Polystyrene Sulfonate Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Sodium Polystyrene Sulfonate Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Sodium Polystyrene Sulfonate Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Patiromer Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Patiromer Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Patiromer Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Sodium Zirconium Cyclosilicate Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Sodium Zirconium Cyclosilicate Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Sodium Zirconium Cyclosilicate Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Vitamin D And Analogs Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Vitamin D And Analogs Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Vitamin D And Analogs Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Active Vitamin D Analogs Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Active Vitamin D Analogs Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Active Vitamin D Analogs Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Nutritional Vitamin D Supplements Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Nutritional Vitamin D Supplements Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Nutritional Vitamin D Supplements Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Calcimimetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Calcimimetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Calcimimetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Diuretics Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Diuretics Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Diuretics Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Loop Diuretics Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Loop Diuretics Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Loop Diuretics Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Thiazide And Thiazide Like Diuretics Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Thiazide And Thiazide Like Diuretics Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Thiazide And Thiazide Like Diuretics Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global Potassium Sparing Diuretics Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Global Potassium Sparing Diuretics Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. Global Potassium Sparing Diuretics Market Size, by Country, 2017-2032 (USD Million)
TABLE 127. Global Uric Acid Lowering Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Global Uric Acid Lowering Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. Global Uric Acid Lowering Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. Global Xanthine Oxidase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Global Xanthine Oxidase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. Global Xanthine Oxidase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 133. Global Uricosuric Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Global Uricosuric Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. Global Uricosuric Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. Global Lipid Lowering Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Global Lipid Lowering Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. Global Lipid Lowering Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 139. Global Statins Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. Global Statins Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. Global Statins Market Size, by Country, 2017-2032 (USD Million)
TABLE 142. Global Ezetimibe And Related Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Global Ezetimibe And Related Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. Global Ezetimibe And Related Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 145. Global PCSK9 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Global PCSK9 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. Global PCSK9 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 148. Global Immunosuppressive Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. Global Immunosuppressive Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. Global Immunosuppressive Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 151. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 154. Global Calcineurin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Global Calcineurin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. Global Calcineurin Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 157. Global Antiproliferative Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Global Antiproliferative Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. Global Antiproliferative Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 160. Global Biologic Immunosuppressants Market Size, by Region, 2017-2032 (USD Million)
TABLE 161. Global Biologic Immunosuppressants Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. Global Biologic Immunosuppressants Market Size, by Country, 2017-2032 (USD Million)
TABLE 163. Global Chronic Kidney Disease Medication Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 164. Global Oral Route Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Global Oral Route Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. Global Oral Route Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. Global Intravenous Route Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Global Intravenous Route Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. Global Intravenous Route Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. Global Subcutaneous Route Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Global Subcutaneous Route Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. Global Subcutaneous Route Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. Global Intramuscular Route Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Global Intramuscular Route Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. Global Intramuscular Route Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. Global Chronic Kidney Disease Medication Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 178. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 180. Global Dialysis Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 181. Global Dialysis Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. Global Dialysis Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 183. Global Nephrology And Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 184. Global Nephrology And Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. Global Nephrology And Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 186. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 187. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 188. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 189. Global Academic And Research Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 190. Global Academic And Research Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 191. Global Academic And Research Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 192. Global Chronic Kidney Disease Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 193. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 194. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 196. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 197. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 199. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 200. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 201. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 202. Global Dialysis Center Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 203. Global Dialysis Center Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 204. Global Dialysis Center Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 205. Global Chronic Kidney Disease Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 206. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 207. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 208. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Renin Angiotensin System Modulators, 2017-2032 (USD Million)
TABLE 209. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Sodium Glucose Cotransporter Inhibitors, 2017-2032 (USD Million)
TABLE 210. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Mineralocorticoid Receptor Antagonists, 2017-2032 (USD Million)
TABLE 211. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Erythropoiesis Stimulating Agents, 2017-2032 (USD Million)
TABLE 212. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Iron Therapies, 2017-2032 (USD Million)
TABLE 213. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Intravenous Iron Therapies, 2017-2032 (USD Million)
TABLE 214. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Oral Iron Therapies, 2017-2032 (USD Million)
TABLE 215. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Phosphate Binders, 2017-2032 (USD Million)
TABLE 216. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Potassium Binders, 2017-2032 (USD Million)
TABLE 217. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Vitamin D And Analogs, 2017-2032 (USD Million)
TABLE 218. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Diuretics, 2017-2032 (USD Million)
TABLE 219. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Uric Acid Lowering Agents, 2017-2032 (USD Million)
TABLE 220. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Lipid Lowering Therapies, 2017-2032 (USD Million)
TABLE 221. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Immunosuppressive Agents, 2017-2032 (USD Million)
TABLE 222. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 223. Asia-Pacific Chronic Kidney Disease Medication Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. Asia-Pacific Chronic Kidney Disease Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. North America Chronic Kidney Disease Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 226. North America Chronic Kidney Disease Medication Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 227. North America Chronic Kidney Disease Medication Market Size, by Renin Angiotensin System Modulators, 2017-2032 (USD Million)
TABLE 228. North America Chronic Kidney Disease Medication Market Size, by Sodium Glucose Cotransporter Inhibitors, 2017-2032 (USD Million)
TABLE 229. North America Chronic Kidney Disease Medication Market Size, by Mineralocorticoid Receptor Antagonists, 2017-2032 (USD Million)
TABLE 230. North America Chronic Kidney Disease Medication Market Size, by Erythropoiesis Stimulating Agents, 2017-2032 (USD Million)
TABLE 231. North America Chronic Kidney Disease Medication Market Size, by Iron Therapies, 2017-2032 (USD Million)
TABLE 232. North America Chronic Kidney Disease Medication Market Size, by Intravenous Iron Therapies, 2017-2032 (USD Million)
TABLE 233. North America Chronic Kidney Disease Medication Market Size, by Oral Iron Therapies, 2017-2032 (USD Million)
TABLE 234. North America Chronic Kidney Disease Medication Market Size, by Phosphate Binders, 2017-2032 (USD Million)
TABLE 235. North America Chronic Kidney Disease Medication Market Size, by Potassium Binders, 2017-2032 (USD Million)
TABLE 236. North America Chronic Kidney Disease Medication Market Size, by Vitamin D And Analogs, 2017-2032 (USD Million)
TABLE 237. North America Chronic Kidney Disease Medication Market Size, by Diuretics, 2017-2032 (USD Million)
TABLE 238. North America Chronic Kidney Disease Medication Market Size, by Uric Acid Lowering Agents, 2017-2032 (USD Million)
TABLE 239. North America Chronic Kidney Disease Medication Market Size, by Lipid Lowering Therapies, 2017-2032 (USD Million)
TABLE 240. North America Chronic Kidney Disease Medication Market Size, by Immunosuppressive Agents, 2017-2032 (USD Million)
TABLE 241. North America Chronic Kidney Disease Medication Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 242. North America Chronic Kidney Disease Medication Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. North America Chronic Kidney Disease Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Latin America Chronic Kidney Disease Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 245. Latin America Chronic Kidney Disease Medication Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 246. Latin America Chronic Kidney Disease Medication Market Size, by Renin Angiotensin System Modulators, 2017-2032 (USD Million)
TABLE 247. Latin America Chronic Kidney Disease Medication Market Size, by Sodium Glucose Cotransporter Inhibitors, 2017-2032 (USD Million)
TABLE 248. Latin America Chronic Kidney Disease Medication Market Size, by Mineralocorticoid Receptor Antagonists, 2017-2032 (USD Million)
TABLE 249. Latin America Chronic Kidney Disease Medication Market Size, by Erythropoiesis Stimulating Agents, 2017-2032 (USD Million)
TABLE 250. Latin America Chronic Kidney Disease Medication Market Size, by Iron Therapies, 2017-2032 (USD Million)
TABLE 251. Latin America Chronic Kidney Disease Medication Market Size, by Intravenous Iron Therapies, 2017-2032 (USD Million)
TABLE 252. Latin America Chronic Kidney Disease Medication Market Size, by Oral Iron Therapies, 2017-2032 (USD Million)
TABLE 253. Latin America Chronic Kidney Disease Medication Market Size, by Phosphate Binders, 2017-2032 (USD Million)
TABLE 254. Latin America Chronic Kidney Disease Medication Market Size, by Potassium Binders, 2017-2032 (USD Million)
TABLE 255. Latin America Chronic Kidney Disease Medication Market Size, by Vitamin D And Analogs, 2017-2032 (USD Million)
TABLE 256. Latin America Chronic Kidney Disease Medication Market Size, by Diuretics, 2017-2032 (USD Million)
TABLE 257. Latin America Chronic Kidney Disease Medication Market Size, by Uric Acid Lowering Agents, 2017-2032 (USD Million)
TABLE 258. Latin America Chronic Kidney Disease Medication Market Size, by Lipid Lowering Therapies, 2017-2032 (USD Million)
TABLE 259. Latin America Chronic Kidney Disease Medication Market Size, by Immunosuppressive Agents, 2017-2032 (USD Million)
TABLE 260. Latin America Chronic Kidney Disease Medication Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 261. Latin America Chronic Kidney Disease Medication Market Size, by End User, 2017-2032 (USD Million)
TABLE 262. Latin America Chronic Kidney Disease Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Europe Chronic Kidney Disease Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 264. Europe Chronic Kidney Disease Medication Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 265. Europe Chronic Kidney Disease Medication Market Size, by Renin Angiotensin System Modulators, 2017-2032 (USD Million)
TABLE 266. Europe Chronic Kidney Disease Medication Market Size, by Sodium Glucose Cotransporter Inhibitors, 2017-2032 (USD Million)
TABLE 267. Europe Chronic Kidney Disease Medication Market Size, by Mineralocorticoid Receptor Antagonists, 2017-2032 (USD Million)
TABLE 268. Europe Chronic Kidney Disease Medication Market Size, by Erythropoiesis Stimulating Agents, 2017-2032 (USD Million)
TABLE 269. Europe Chronic Kidney Disease Medication Market Size, by Iron Therapies, 2017-2032 (USD Million)
TABLE 270. Europe Chronic Kidney Disease Medication Market Size, by Intravenous Iron Therapies, 2017-2032 (USD Million)
TABLE 271. Europe Chronic Kidney Disease Medication Market Size, by Oral Iron Therapies, 2017-2032 (USD Million)
TABLE 272. Europe Chronic Kidney Disease Medication Market Size, by Phosphate Binders, 2017-2032 (USD Million)
TABLE 273. Europe Chronic Kidney Disease Medication Market Size, by Potassium Binders, 2017-2032 (USD Million)
TABLE 274. Europe Chronic Kidney Disease Medication Market Size, by Vitamin D And Analogs, 2017-2032 (USD Million)
TABLE 275. Europe Chronic Kidney Disease Medication Market Size, by Diuretics, 2017-2032 (USD Million)
TABLE 276. Europe Chronic Kidney Disease Medication Market Size, by Uric Acid Lowering Agents, 2017-2032 (USD Million)
TABLE 277. Europe Chronic Kidney Disease Medication Market Size, by Lipid Lowering Therapies, 2017-2032 (USD Million)
TABLE 278. Europe Chronic Kidney Disease Medication Market Size, by Immunosuppressive Agents, 2017-2032 (USD Million)
TABLE 279. Europe Chronic Kidney Disease Medication Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 280. Europe Chronic Kidney Disease Medication Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. Europe Chronic Kidney Disease Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 282. Middle East Chronic Kidney Disease Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 283. Middle East Chronic Kidney Disease Medication Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 284. Middle East Chronic Kidney Disease Medication Market Size, by Renin Angiotensin System Modulators, 2017-2032 (USD Million)
TABLE 285. Middle East Chronic Kidney Disease Medication Market Size, by Sodium Glucose Cotransporter Inhibitors, 2017-2032 (USD Million)
TABLE 286. Middle East Chronic Kidney Disease Medication Market Size, by Mineralocorticoid Receptor Antagonists, 2017-2032 (USD Million)
TABLE 287. Middle East Chronic Kidney Disease Medication Market Size, by Erythropoiesis Stimulating Agents, 2017-2032 (USD Million)
TABLE 288. Middle East Chronic Kidney Disease Medication Market Size, by Iron Therapies, 2017-2032 (USD Million)
TABLE 289. Middle East Chronic Kidney Disease Medication Market Size, by Intravenous Iron Therapies, 2017-2032 (USD Million)
TABLE 290. Middle East Chronic Kidney Disease Medication Market Size, by Oral Iron Therapies, 2017-2032 (USD Million)
TABLE 291. Middle East Chronic Kidney Disease Medication Market Size, by Phosphate Binders, 2017-2032 (USD Million)
TABLE 292. Middle East Chronic Kidney Disease Medication Market Size, by Potassium Binders, 2017-2032 (USD Million)
TABLE 293. Middle East Chronic Kidney Disease Medication Market Size, by Vitamin D And Analogs, 2017-2032 (USD Million)
TABLE 294. Middle East Chronic Kidney Disease Medication Market Size, by Diuretics, 2017-2032 (USD Million)
TABLE 295. Middle East Chronic Kidney Disease Medication Market Size, by Uric Acid Lowering Agents, 2017-2032 (USD Million)
TABLE 296. Middle East Chronic Kidney Disease Medication Market Size, by Lipid Lowering Therapies, 2017-2032 (USD Million)
TABLE 297. Middle East Chronic Kidney Disease Medication Market Size, by Immunosuppressive Agents, 2017-2032 (USD Million)
TABLE 298. Middle East Chronic Kidney Disease Medication Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 299. Middle East Chronic Kidney Disease Medication Market Size, by End User, 2017-2032 (USD Million)
TABLE 300. Middle East Chronic Kidney Disease Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 301. Africa Chronic Kidney Disease Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 302. Africa Chronic Kidney Disease Medication Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 303. Africa Chronic Kidney Disease Medication Market Size, by Renin Angiotensin System Modulators, 2017-2032 (USD Million)
TABLE 304. Africa Chronic Kidney Disease Medication Market Size, by Sodium Glucose Cotransporter Inhibitors, 2017-2032 (USD Million)
TABLE 305. Africa Chronic Kidney Disease Medication Market Size, by Mineralocorticoid Receptor Antagonists, 2017-2032 (USD Million)
TABLE 306. Africa Chronic Kidney Disease Medication Market Size, by Erythropoiesis Stimulating Agents, 2017-2032 (USD Million)
TABLE 307. Africa Chronic Kidney Disease Medication Market Size, by Iron Therapies, 2017-2032 (USD Million)
TABLE 308. Africa Chronic Kidney Disease Medication Market Size, by Intravenous Iron Therapies, 2017-2032 (USD Million)
TABLE 309. Africa Chronic Kidney Disease Medication Market Size, by Oral Iron Therapies, 2017-2032 (USD Million)
TABLE 310. Africa Chronic Kidney Disease Medication Market Size, by Phosphate Binders, 2017-2032 (USD Million)
TABLE 311. Africa Chronic Kidney Disease Medication Market Size, by Potassium Binders, 2017-2032 (USD Million)
TABLE 312. Africa Chronic Kidney Disease Medication Market Size, by Vitamin D And Analogs, 2017-2032 (USD Million)
TABLE 313. Africa Chronic Kidney Disease Medication Market Size, by Diuretics, 2017-2032 (USD Million)
TABLE 314. Africa Chronic Kidney Disease Medication Market Size, by Uric Acid Lowering Agents, 2017-2032 (USD Million)
TABLE 315. Africa Chronic Kidney Disease Medication Market Size, by Lipid Lowering Therapies, 2017-2032 (USD Million)
TABLE 316. Africa Chronic Kidney Disease Medication Market Size, by Immunosuppressive Agents, 2017-2032 (USD Million)
TABLE 317. Africa Chronic Kidney Disease Medication Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 318. Africa Chronic Kidney Disease Medication Market Size, by End User, 2017-2032 (USD Million)
TABLE 319. Africa Chronic Kidney Disease Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 320. Global Chronic Kidney Disease Medication Market Size, by Group, 2017-2032 (USD Million)
TABLE 321. ASEAN Chronic Kidney Disease Medication Market Size, by Group, 2017-2032 (USD Million)
TABLE 322. ASEAN Chronic Kidney Disease Medication Market Size, by Drug Clas

Companies Mentioned

  • Amgen Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer Aktiengesellschaft
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Fresenius Medical Care AG & Co. KGaA
  • Otsuka Pharmaceutical Co., Ltd.
  • Sanofi S.A.
  • Vifor Pharma AG

Related Topics

Related Reports

Late Stage Chronic Kidney Disease Therapeutics Market - Global Forecast 2026-2032 - Product Image

Late Stage Chronic Kidney Disease Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Chronic Kidney Disease (CKD) Drugs - Global Strategic Business Report - Product Image

Chronic Kidney Disease (CKD) Drugs - Global Strategic Business Report

  • Report
  • 347 Pages
  • Global
From
Nephrology Drugs Market Report 2026 - Product Image

Nephrology Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Diabetic Nephropathy Treatment Market - Global Forecast 2026-2032 - Product Image

Diabetic Nephropathy Treatment Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Chronic Kidney Disease - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Chronic Kidney Disease - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 114 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.